Endocrinology

Your Article Summary

See Latest Articles

Vildagliptin in clinical practice: a review of literature
Expert Opinion in Pharmacotherapy, 11/03/09

Banerjee M et al. – Vildagliptin is the second member of the DPP–IV inhibitor class of drugs licensed for the treatment of type 2 diabetes mellitus. The novel action of these drugs has promoted a new outlook in the pathobiology of T2DM. This review undertakes to examine the clinical studies published to date, with the aim of evaluating the position of vildagliptin among the drugs that are now available to treat this common dysmetabolic state.

Today in Diabetes...keeping you current

Receive free subspecialty "5-minute updates" via email

Individuation of different metabolic phenotypes in normal glucose tolerance test
Acta Diabetologia, 11/25/09

Psychometric properties and responsiveness of the Turkish version of the Diabetes Treatment Satisfaction Questionnaire (s) on a sample of diabetics of three consecutive monitoring periods
Acta Diabetologia, 11/25/09

Serum glycated albumin, but not glycated haemoglobin, is low in relation to glycemia in hyperuricemic men
Acta Diabetologia, 11/25/09

 See all of Diabetes

Today in Pharmacology/kinetics...keeping you current

Receive free subspecialty "5-minute updates" via email

Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome
Diabetes Care, 11/25/09

Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight
International Journal of Obesity, 11/25/09

Assessment of Regional Changes in Skeletal Metabolism Following 3 and 18 Months of Teriparatide Treatment
Journal of Bone and Mineral Research, 11/25/09

 See all of Pharmacology/kinetics